Vanda Pharmaceuticals Announces Presentations at DDW 2023
Get Alerts VNDA Hot Sheet
Join SI Premium – FREE
The following will be presented:
Presentation Title: "THE ROLE OF TENASCIN-X IN IDIOPATHIC GASTROPARESIS: WGS ANALYSIS"
Poster Number: Su1618
Presenter: Dr.
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time:
Presentation Title: "POOLED EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS STUDY VP-VLY-686-3301 AND VP-VLY-686-2301"
Poster Number: Su1632
Presenter: Dr.
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time:
Presentation Title: "EFFICACY ANALYSIS OF TRADIPITANT IN IDIOPATHIC AND DIABETIC GASTROPARESIS IN STUDY VP-VLY-686-3301"
Poster Number: Su1633
Presenter: Dr.
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time:
Presentation Title: "A BASELINE SEVERITY INFLATION ANALYSIS IN STUDY VP-VLY-686-3301 OF TRADIPITANT IN GASTROPARESIS"
Poster Number: Su1634
Presenter: Dr.
Session Type: Poster Session
Session Title: AGA Gastroparesis and Small Intestinal Dysmotility
Session Time:
For more information on DDW 2023, please refer to https://ddw.org/.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.
Corporate Contact:
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected]
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected]
View original content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-presentations-at-ddw-2023-301816683.html
SOURCE Vanda Pharmaceuticals Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- APP Group and Charta Global Strengthen Access to the Sustainable Packaging Market at PPC Spring Meeting 2026
- Connecting Excellence Group PLC Announces Treasury up By 10 BTC to 72.941 & £655,999 Raised
- EFICAS Study Results Confirm the Clinical Performance of the Aeson® Total Artificial Heart as a Bridge-to-Transplant Therapy
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share